fda compounding glp-1 crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The FDA crackdown on compounded

Your potential goes to waste

The difference is that you are more likely to have unused solution in the 60 mg vial if you are on a low dose

[3] Next-Generation Dual and Multi-Targeted Therapies on the Rise Amycretin: A Promising Dual GLP-1/Amylin Receptor Agonist Also making headlines at ADA 2025 was Amycretin (NNC0487-0111), a novel, unimolecular GLP-1 and amylin receptor agonist under development by Novo Nordisk

Obesity and early mortality in the United States

Case Info Ozempic Mounjaro GLP-1 Gastroparesis Lawsuit Popular GLP-1 medications used for diabetes and weight loss may cause severe side effects which may result in hospitalization, permanent injury, or other serious complications

In theory, 1 g of edetate calcium can theoretically bind 620 mg of lead, but in reality only about 5 mg per gram is actually excreted into the urine in lead poisoned patients